임상 레이더 AI | ||
|---|---|---|
임상시험 NCT07047612은(는) Non Segmental Vitiligo에 대해 모집중 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요. | ||
ICP-332 in Subjects With Non-segmental Vitiligo 2상, 3상 603 무작위 배정 이중 눈가림 위약 대조 적응형 설계
A Phase II/III Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive Design, Multi-center Study to Evaluate the Efficacy and Safety of ICP-332 in Subjects With Non-segmental Vitiligo
- ICP-CL-00607
3상
| 참가자 그룹/시험군 | 개입/치료 |
|---|---|
실험적ICP-332 dose A(Phase2) | ICP-332 Tablets ICP-332 will be administered as tablet |
위약 대조군Placebo(Phase2) | ICP-332 Placebo Tablets ICP-332 Placebo will be administered as tablet |
실험적ICP-332 dose B(Phase2:) | ICP-332 Tablets ICP-332 will be administered as tablet |
실험적ICP-332 dose A or dose B(Phase3) | ICP-332 Tablets ICP-332 will be administered as tablet |
위약 대조군Placebo(Phase3) | ICP-332 Placebo Tablets ICP-332 Placebo will be administered as tablet |
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Phase2: Percent change from baseline in facial vitiligo area scoring index (F-VASI) at week 24. | 24 weeks | |
Phase3: Proportion of subjects achieving F-VASI 75 at Week 52. | 52 weeks |
Male or female subjects aged ≥18 years and ≤75 years (Phase II portion). Male or female subjects ≥12 years of age and ≤75 years of age, adolescent subjects must weigh ≥40 kg (Phase III portion).
Eligible subjects must meet all of the following criteria at screening and baseline:
- The clinical diagnosis was non-segmental vitiligo for at least 3 months.
- Involvement of BSA≥5%.
- Facial involvement BSA≥0.5%.
- F-VASI≥0.5 and T-VASI between 5 and 50.
- Active or stable non-segmental vitiligo was present at both screening and baseline visits.
Women of childbearing potential (WOCBP) and Men must agree to contraception.
Before beginning any screening or study specific procedures, subjects must voluntarily sign informed consent.
Any of the following vitiligo related medical conditions and other skin diseases/conditions.
a) Subjects had other types of vitiligo (including but not limited to segmental vitiligo and mixed vitiligo) that did not meet the criteria for active or stable vitiligo described in Inclusion criteria 2.
History of any clinically major diseases, with the exception of vitiligo.
Pregnant or breastfeeding females.
The investigator considers that the subject is not suitable for participation in this study for any reason.
Anhui
Beijing Municipality
Chongqing Municipality
Fujian
Guangdong
Hebei
Henan
Hubei
Hunan
Jiangsu
Jiangxi
Jilin
Liaoning
Shandong
Shanghai Municipality
Shanxi
Sichuan
Yunnan
Zhejiang